{"prompt": "['9.1.2 YMRS', '42', '9.1.3', 'Abnormal Involuntary Movement Scale', '42', '9.1.4', 'Barnes Akathisia Rating Scale', '42', '9.1.5', 'Simpson-Angus Scale', '42', '9.1.6', 'Vital Sign Measurements', '43', '9.1.7', 'ECG Assessments', '43', '9.1.8', 'Physical and Neurological Examination', '43', '9.1.9', 'Unanticipated Problems', '43', '9.1.10 Adverse Events', '45', '9.1.11 Serious Adverse Events', '46', '9.2', 'Time Period and Frequency for Event Assessment and Follow-Up', '47', '9.3', 'Characteristics of an Adverse Event', '47', '9.3.1 Relationship to Study Intervention', '47', '9.3.2', 'Expectedness of SAEs', '48', '9.3.3', 'Severity of Event', '49', '9.4', 'Reporting Procedures', '49', '9.4.1', 'Unanticipated Problem Reporting to IRB/IEC', '50', '9.4.2', 'Serious Adverse Event Reporting to the Sponsor', '50', '9.4.3', 'Reporting of SAEs and AEs to FDA and Other Regulatory Authorities', '52', '9.4.4', 'Reporting of Pregnancy', '52', '9.5', 'Halting Rules', '52', '10', 'STUDY OVERSIGHT', '53', '10.1 External Data Monitoring Committee', '53', '11', 'CLINICAL SITE MONITORING', '54', '12', 'STATISTICAL CONSIDERATIONS', '55', '12.1', 'Sample Size Considerations', '55', '12.2', 'Planned Interim Analyses (if applicable)', '55', '12.3', 'Analysis Sets', '55', '12.4', 'Statistical Analysis Methodology', '56', '12.4.1 Patient Disposition, Analysis of Demographics and Other Baseline', 'Characteristics', '57', '12.4.2 Prior and Concomitant Medications', '58', '12.4.3 Study Medication Exposure and Treatment Compliance', '58', '12.4.4 Analysis of Primary and Key Secondary Efficacy Endpoints', '58', '12.4.5 Analysis of Other Secondary Efficacy Endpoints', '61', '12.4.6 Pharmacokinetic Analyses', '63', '13', 'SOURCE DOCUMENTS AND ACCESS TO SOURCE DATA/DOCUMENTS', '64', '14', 'QUALITY CONTROL AND QUALITY ASSURANCE', '65', '15', 'ETHICS/PROTECTION OF HUMAN SUBJECTS', '66', '15.1', 'Ethical Standard', '66', '15.2', 'Independent Ethics Committee or Institutional Review Board', '66', '15.3', 'Ethical Conduct of the Study', '66', '15.4', 'Institutional Review Board', '66', '15.5', 'Informed Consent Process', '67', 'Intra-Cellular Therapies, Inc. Confidential', 'vi ITI-007-404 Protocol Amendment V 1.3 November 5, 2018']['15.6', 'Patient Information and Consent', '67', '15.7', 'Patient Confidentiality', '68', '15.8', 'Future Use of Stored Specimens and Other Identifiable Data', '68', '16', 'DATA HANDLING AND RECORD KEEPING', '69', '16.1', 'Data Management Responsibilities', '70', '16.2', 'Data Capture Methods', '70', '16.3', 'Types of Data', '70', '16.4', 'Schedule and Content of Reports', '70', '16.5', 'Study Records Retention', '70', '16.6', 'Protocol Deviations', '70', '17', 'PUBLICATION/DATA SHARING POLICY', '72', '18', 'LITERATURE REFERENCES', '73', 'SUPPLEMENTAL MATERIALS', '75', 'APPENDIX A: SCHEDULE OF EVENTS', '76', 'Intra-Cellular Therapies, Inc. Confidential', 'vii ITI-007-404 Protocol Amendment V 1.3 November 5, 2018']\n\n###\n\n", "completion": "END"}